Browsing Tag
Susvimo
4 posts
EyePoint reaches full DME enrollment with $222.5m and a runway ending near the readout
EyePoint completes Phase 3 DME enrollment as DURAVYU targets six-month dosing, with wet AMD data due in August and DME results in late 2027.
Susvimo EU recommendation gives Roche a new weapon in the battle for longer-lasting eye treatments
Roche moves Susvimo toward EU approval as its refillable eye implant targets injection burden and strengthens a CHF 2.1 billion retinal franchise.
Breakthrough in diabetes care: Roche’s Susvimo could revolutionize eye treatment
Roche, a global leader in pharmaceuticals and diagnostics, recently unveiled two-year data from the pivotal Phase III Pagoda…
Genentech announces reintroduction of Susvimo for Wet AMD treatment in US
Genentech, a key member of the Roche Group, has officially announced the reintroduction of Susvimo (ranibizumab injection) 100…